Kite's Car T-cell Therapy Yescarta® Demonstrates High R

– Yescarta Achieved a Complete Metabolic Response of 71% at 3 Months Versus 12% Expected with Historical Standard of Care Controls –


– Results Published in Nature Medicine–

...

Related Keywords

Portugal , California , United States , Santa Monica , Belgium , France , Rennes , Bretagne , Foster City , French , Frank Neumann , Roch Houot , Gilead Sciences Inc , Lymphoma Study Association , Collaborative Group , Gilead Company Nasdaq , Gilead Company , Kite Global Head Of Clinical Development , Lymphoma Academic Research Organization , Head Of Haematology Department , University Hospital Of Rennes , Exchange Commission , Gilead Sciences , Haematology Department , University Hospital , Global Head , Prescribing Information , Release Syndrome , Risk Evaluation , Mitigation Strategy , Private Securities Litigation Reform Act , Quarterly Report , Markets ,